<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Allogeneic hematopoietic cell transplantation (HCT) is the only curative strategy for patients with <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) and <z:hpo ids='HP_0005547'>myeloproliferative disorders</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MPD</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>We report the results of 148 patients (median age = 59 years old) with de novo <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> (n = 40), <z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) after antecedent <z:e sem="disease" ids="C1301355" disease_type="Neoplastic Process" abbrv="">MDS/MPD</z:e> (n = 49), treatment-related <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> (t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) (n = 25), <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MPD</z:e> (n = 27), and <z:hpo ids='HP_0011010'>chronic</z:hpo> myelomonocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e>) (n = 7) who underwent allogeneic HCT using a conditioning regimen of low-dose total body irradiation (TBI) alone (200 cGy) on day 0 (n = 5) or with the addition of fludarabine (Flu) 30 mg/m(2)/day on days -4 to -2 (n = 143) </plain></SENT>
<SENT sid="2" pm="."><plain>Postgrafting immunosuppression consisted of <z:chebi fb="0" ids="4031">cyclosporine</z:chebi> and <z:chebi fb="0" ids="168396">mycophenolate</z:chebi> mofetil (MMF) </plain></SENT>
<SENT sid="3" pm="."><plain>Seventy-five patients (51%) received an allograft from a matched related donor (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MRD</z:e>), and 73 patients (49%) were recipients of unrelated donor (URD) grafts </plain></SENT>
<SENT sid="4" pm="."><plain>There was no significant difference in the incidence of <z:hpo ids='HP_0011009'>acute</z:hpo> (gr II-IV) and <z:hpo ids='HP_0011010'>chronic</z:hpo> extensive <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host disease</z:e> (aGVHD, cGVHD) between the recipients of related and unrelated donor grafts </plain></SENT>
<SENT sid="5" pm="."><plain>By day +28, 75% of patients demonstrated mixed T cell chimerism </plain></SENT>
<SENT sid="6" pm="."><plain>Graft rejection was seen in 15% of patients </plain></SENT>
<SENT sid="7" pm="."><plain>With a median follow-up of 47 (range: 6-89) months, the 3-year relapse-free survival (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RFS</z:e>) and overall survival (OS) are both 27% for <z:hpo ids='HP_0000001'>all</z:hpo> patients, with a relapse incidence of 41% </plain></SENT>
<SENT sid="8" pm="."><plain>The 3-year <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RFS</z:e> for the patients with de novo <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> after antecedent <z:e sem="disease" ids="C1301355" disease_type="Neoplastic Process" abbrv="">MDS/MPD</z:e>, t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MPD</z:e>, and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e> were 22%, 20%, 29%, 37%, and 43%, respectively, and the 3-year OS was 20%, 23%, 27%, 43%, and 43%, respectively </plain></SENT>
<SENT sid="9" pm="."><plain>The 3-year nonrelapse mortality (NRM) was 32% </plain></SENT>
<SENT sid="10" pm="."><plain>Factors associated with a lower risk of relapse were the development of extensive cGVHD and having a low risk or intermediate-1 risk International Prognostic Score for the de novo <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients </plain></SENT>
<SENT sid="11" pm="."><plain>Nonmyeloablative HCT confers remissions in patients who otherwise were not eligible for conventional HCT but for whom relapse is the leading cause of treatment failure </plain></SENT>
</text></document>